Tag Archives: business development

Jonathan Wolfson Receives the George Washington Carver Award!

Jonathan S. Wolfson

“What is possible, is far more than what people think.” – Wolfson On Monday at the BIO World Congress on Industrial Biotechnology, Jonathan S. Wolfson, Chief Executive Officer of Solazyme, received BIO’s George Washington Carver Award. The Award was given during the Lunch Plenary Session titled State and Regional Approaches to Developing the Biobased Economy & George Washington Carver Award for Innovation in Industrial Biotechnology Presentation. The Governor of Iowa, Terry Branstad, and BIO’s Executive Read More >

Environmental & Industrial, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

13 Days Until BIO 2015: Moneyball: Acing the Big Pharma/Small Biotech Deal

BIO Business Networking

In just a few weeks, thousands of players in the pharma and biotech industry will converge on Philadelphia for BIO 2015 seeking knowledge, insight and, for many, the ultimate goal – new partnerships. Collaboration is often the key to success for emerging biotech companies and big pharma alike as it can open the door to new markets, influencers and revenue streams. In oncology, deals between established pharmaceutical companies and early-stage biotechs are especially relevant and Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Professional Development Opportunities at BIO 2015

ExecTraining_115x76_

BIO offers two executive training courses to help attendees grow professionally, both co-located at the 2015 BIO International Convention in Philadelphia, PA from June 13-15, 2015. The Business Development Fundamentals and Advanced Business Development courses support the activity that takes place at our partnering and investor conferences each year by training individuals who are making the deals that drive this industry. Each course is taught by experienced business development professionals from leading pharmaceutical and biotechnology Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

PTO Patent Examinations in the wake of Mayo and Myriad

stopped-media-115x76

Biotech patent applicants are finding themselves in uncharted waters.   After the Supreme Court’s decisions in Mayo Collaborative Svs. v. Prometheus Labs and Ass’n for Molecular Pathology v. Myriad Genetics, companies have been trying to understand how these decisions will impact the industry. A recent study supported by BIO, in collaboration with Bloomberg BNA and the law firm of Robins, Kaplan, Miller & Ciresi analyzed how Mayo and Myriad have changed patent eligibility for biotechnology. Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , ,

The Most Linked In Man in Biotech Retires after 35 Years

Chris Y

The biotech world loses one of its preeminent titans of business development this year with the retirement of Chris Yochim. Variously dubbed “the face of AstraZeneca”, “Mr. Conference”, and other monikers as colorful as his dress shirts, Chris concludes a career spanning 35 years in the pharmaceutical industry. Trained as a pharmacologist, he contributed to the identification of several candidate compounds that are marketed drugs today, but more than anything else, Chris is known as Read More >

Events  |  1 Comment  |  Email This Post
Tags: , , , , , , , ,